Fewer than one in 10 patients that would benefit from weight-loss injections like Wegovy can access them, warns the World Health Organization as it issues its inaugural guidance on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
Per forecasts, more than two billion will be obese by 2030 if no action is taken.
"The new guidelines acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are significant hurdles to broad access to the treatments that can help people shift substantial body mass, explains the organization.
GLP-1 Therapy Scarcity
Even in the present best projected case, the supply of these medications could only cover approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline urges countries and companies to expand access, through approaches like patent sharing.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Jabs Operate
GLP-1 drugs mimick a natural hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals consume fewer calories.
People typically start to lose weight within a few weeks of starting on the regular doses.
Evidence points to patients may see weight return within a year of discontinuing the drug, when their normal hunger return.
Being carrying excess weight raises your likelihood for contracting health problems, like diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight concerns individuals in all nations and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
